Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?
Translational Gastroenterology and Hepatology · 2026-01 · 11 · 1-1
DOI: 10.21037/tgh-25-34 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-01. Verfasst von Maen Abdelrahim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Section of GI Oncology, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of GI Oncology, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
- Department of Gastroenterology & Hepatology, Faculty of Medicine, The University of Jordan, Amman, Jordan.
- Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia.
Zitieren
APA
Abdelrahim, M., Esmail, A., & Al-Judaibi, B. (2026). Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?. Translational Gastroenterology and Hepatology, 11, 1-1. https://doi.org/10.21037/tgh-25-34
Vancouver
Abdelrahim M, Esmail A, Al-Judaibi B. Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?. Translational Gastroenterology and Hepatology. 2026;11:1-1. doi:10.21037/tgh-25-34
BibTeX
@article{Abdelrahim2026,
author = {Abdelrahim, Maen and Esmail, Abdullah and Al-Judaibi, Bandar},
title = {Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?},
journal = {Translational Gastroenterology and Hepatology},
year = {2026},
volume = {11},
pages = {1--1},
doi = {10.21037/tgh-25-34}
}
EUVIMED